Re: Genomic Differences between "Primary" and "Secondary" Muscle-Invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-Based Neoadjuvant Chemotherapy

J Urol. 2019 Jul;202(1):30. doi: 10.1097/01.JU.0000557728.16853.8f. Epub 2019 Jun 7.
No abstract available

Publication types

  • Comment

MeSH terms

  • Chemotherapy, Adjuvant
  • Cisplatin*
  • Cystectomy
  • Genomics
  • Humans
  • Neoadjuvant Therapy
  • Urinary Bladder Neoplasms*

Substances

  • Cisplatin